



# Promoting Patient Safety Best Practices in Japan

**Shin Ushiro M.D., PhD.**  
**Kyushu University Hospital**  
**Japan Council for Quality Health Care (JQ)**  
**International Society for Quality in Health Care (ISQua)**  
**Ministry of Health, Labour and Welfare (MoHLW), Japan**

# Project line-up of JQ on Quality and Safety Improvement

## Hospital Accreditation

Patient Safety Promotion Group of Among Accredited Hospitals

Education and Training on Patient Safety

EBM Medical Information Distribution Project (Minds)

## Nationwide Adverse Events Reporting System of Medical Institutions


## Nationwide Near-miss Event Reporting System of Community Pharmacy

## The Japan Obstetric Compensation/Investigation and Prevention System for Cerebral Palsy


National Quality Indicator (QI) Measurement Project

**Patient representatives** participate in the operation of most projects.


# Nationwide reporting/investigation/learning system with public or quasi public nature



# Overview of the nationwide adverse event reporting/learning system (2004 - )



# Trajectory of the AE reporting to JQ



**5,313** AEs / 2022 were reported.



# Japan National University Hospital Alliance on Patient Safety (JANUHA-PS) Annual Congress, 2022

Chair; Nagoya University Hospital, Vice chair; Tohoku University Hospital




**BEFORE**  
YOU TAKE IT...


**KNOW**  
your medication

**CHECK**  
the dose and time

**ASK**  
your health care professional



**MEDICATION**  
Management  
Global Patient Safety Challenge



World Health Organization






## Contents of Annual/Quarterly report \*

- Outline of the system
- Numerical analysis
- Thematic analysis
  - i. “New themes; 252 themes
  - ii. “Recurrent” themes; 134 themes

\* 72 Quarterly reports & 17 Annual reports

# Types of Adverse Event



Medication

Blood transfusion

Procedures

Medical devices

Tubes

Examinations & Lab tests

Nursing care

Others

2019 Annual Report of JQ's AE/Near-miss reporting system



# Themes of analysis in past quarterly reports

|                             |   |
|-----------------------------|---|
| 72nd report<br>(Marr, 2023) | Failed "Double-check"   |
|                             | Error in setting "Unit" on infusion pump                              |
| 71st report<br>(Dec, 2022)  | Wrong-patient care (series 4)   |
|                             | Failed sensing system to detect patient movement for preventing falls |
| 70th report<br>(Sep, 2021)  | Wrong-patient care (series 3)   |
| 69th report<br>(Sep, 2021)  | Wrong-patient care (series 2)   |
| 68th report<br>(Jun, 2021)  | Wrong-patient care (series 1)   |
|                             | Event related to Covid-19 infection (series 2)                        |
| 67th report<br>(Apr, 2021)  | Medication error related to chemotherapy for outpatient (series 2)    |
|                             | Pressure ulcer developed by medical devices                           |



# Failure to Confirm CT, MRI Imaging Report

## Thematic analysis

## Monthly Alert

再発・類似事例の分析 「画像診断報告書の確認不足」(医療安全情報 No. 6.3)

【2】「画像診断報告書の確認不足」(医療安全情報 No. 6.3)

(1) 発生状況

画像診断報告書の内容が伝達されなかった事例について、第26回報告書(2011年9月公表)において、画像診断報告書を見なかった事例と画像診断報告書の記載内容を見落とす事例に大別して分析を行った。その後、医療安全情報 No. 6.3(2012年2月提供; 集計期間: 2008年1月~2011年12月)では「画像診断報告書の確認不足」として、画像検査を行った際、画像診断報告書が報告されているにもかかわらず内容を確認しなかったため、想定していなかった診断に気付かず、治療の遅れを生じた可能性のある事例について取り上げた。さらに、第40回報告書(2015年3月公表)の「再発・類似事例の発生状況」において、医療安全情報 No. 6.3「画像診断報告書の確認不足」について、新たに報告された事例を紹介し、画像検査の目的と画像診断報告書を確認していなかった背景・要因について取りまとめた。

今回、本報告書分析対象期間(2017年7月~9月)においても類似の事例が13件報告されたため、再び取り上げることとした。第40回報告書の集計期間後の2015年1月以降に報告された再発・類似事例は32件であった(図表III-3-4)。

図表III-3-4 「画像診断報告書の確認不足」の報告件数

|       | 1~3月(件) | 4~6月(件) | 7~9月(件) | 10~12月(件) | 合計(件) |
|-------|---------|---------|---------|-----------|-------|
| 2015年 | 3       | 2       | 2       | 4         | 11    |
| 2016年 | 0       | 0       | 3       | 1         | 4     |
| 2017年 | 2       | 2       | 13      | —         | 17    |

図表III-3-5 医療安全情報 No. 6.3 「画像診断報告書の確認不足」

Japan Council for Quality Health Care

Project to Collect Medical Near-Miss/Adverse Event Information

Medical Safety Information No.191, October 2022

### Local Injection of High-Concentration Adrenaline Due to Container Mix-Up

Three cases have been reported in which high-concentration adrenaline was erroneously injected when injecting local anesthetic during surgery, due to the wrong container being picked up (information collection period: from January 1, 2019 to August 31, 2022). This information was compiled on the basis of the content featured in the Details of Events section of the 69th Quarterly Report.

Cases have been reported in which the local injection of high-concentration adrenaline during surgery due to picking up the wrong container affected the patient's hemodynamics.

| Concentration of Adrenaline as Local Anesthetic | Concentration of Adrenaline Injected | Main Background Factors   | Image of case |
|---|--------------------------------------|---|---------------|
| 1:200,000 concentration                         | 1:1,000 concentration                | <ul style="list-style-type: none"> <li>Prepared in a medicine cup with the same shape</li> <li>Could not see the label affixed to the side</li> </ul>   |               |
| 1:300,000 concentration                         | 1:1,000 concentration                | <ul style="list-style-type: none"> <li>The location and presence or absence of a lid were usually used to distinguish the two, but the lid was removed and the dish was placed next to the other</li> </ul>             |               |
| 1:100,000 concentration                         | 1:5,000 concentration                | <ul style="list-style-type: none"> <li>Prepared in a medicine cup with the same shape</li> <li>The containers were put in separate places, but the container had been moved and placed nearer during surgery</li> </ul> |               |

◆ In the reported cases, the two drugs were placed in containers with the same shape and the drug name was written on one or both of the containers.

Project to Collect Medical Near-Miss/Adverse Event Information

Medical Safety Information No.191, October 2022

### Local Injection of High-Concentration Adrenaline Due to Container Mix-Up

**Case 1**

In the sterilized area, the nurse prepared a Xyloaine preparation (1:200,000 concentration of adrenaline) in a medicine cup bearing the label "Xylo 1% E + NS" and Bosmin Solution 0.1% (1:1,000 concentration of adrenaline) in a medicine cup bearing the label "Bosmin topical." The physician first used the Xyloaine preparation for local anesthesia. Thinking that the physician would next use a gauze impregnated with Bosmin, the nurse placed the medicine cup marked "Bosmin (topical)" in front. The physician then ordered local anesthetic for a second time. The nurse drew up the drug solution from the medicine cup in front, without checking the label on the side, and passed it to the physician. After the physician injected a total of 4 mL, the patient's blood pressure rose to 230/130 mmHg and their heart rate to 130 bpm, with sporadic premature ventricular contractions and ST segment depression observed on the monitor. The nurse realized that they had handed over Bosmin Solution 0.1% in error.

**Case 2**

The nurse prepared a Xyloaine preparation (1:300,000 concentration of adrenaline) and Bosmin Solution 0.1% (1:1,000 concentration of adrenaline) in Petri dishes of the same shape and placed them on the instrument tray. The nurse had placed the two Petri dishes away from each other and written the drug name on the lid of the Petri dish containing the Xyloaine preparation. After surgery began, the physician ordered a Bosmin swab, so the nurse placed the Petri dish containing Bosmin Solution 0.1% next to the Petri dish containing the Xyloaine preparation. The physician subsequently ordered local anesthetic, so the nurse drew up the drug solution from the Petri dish and handed it to the physician. After the physician injected 4 mL, the patient's blood pressure rose to 270 mmHg and the nurse realized that they had handed over Bosmin Solution 0.1% in error.

Preventive measures taken at the medical institutions in which the events occurred

- Use containers with different shapes and label them with the drug name in an easily visible location when preparing local anesthetic and adrenaline preparations in the sterilized area.
- The measure above is an example. Please consider initiatives suitable for your own facility.

Key Preventive Measures

- Consider changing the shape and color of containers, and prescribe internal rules.

(Comprehensive Evaluation Panel)

◆ As part of the Project to Collect Medical Near-Miss/Adverse Event Information (a Ministry of Health, Labour and Welfare grant project), this medical safety information was prepared based on the cases collected in the Project as well as on opinions of the "Comprehensive Evaluation Panel" to prevent the occurrence and recurrence of medical adverse events. See the Project website for details. <http://www.med-safe.jp/>

◆ Accuracy of information was ensured at the time of preparation but cannot be guaranteed in the future.

◆ This information is intended neither to limit the discretion of healthcare providers nor to impose certain obligations or responsibilities on them.

Department of Adverse Event Prevention  
Japan Council for Quality Health Care

1-4-17 Kandamatsubashi-cho, Chiyoda-ku, Tokyo 101-0001 JAPAN  
Direct Tel: +81-3-5217-0252 Direct Fax: +81-3-5217-0253  
<https://www.med-safe.jp/>



# Monthly alert produced in RLS

Medical Safety Information, Project to Collect Medical Near-Miss/Adverse Event Information

**Japan Council for Quality Health Care**

**Medical Safety Information**  
No.191, October 2022

**Local Injection of High-Concentration Adrenaline Due to Container Mix-Up**

Three cases have been reported in which high-concentration adrenaline was erroneously injected when injecting local anesthetic during surgery, due to the wrong container being picked up (information collection period: from January 1, 2019 to August 31, 2022). This information was compiled on the basis of the content featured in the Details of Events section of the 69th Quarterly Report.

**Cases have been reported in which the local of high-concentration adrenaline during surge picking up the wrong container affected the hemodynamics.**

| Concentration of Adrenaline as Local Anesthetic | Concentration of Adrenaline injected | Main Background Factors   |
|---|--------------------------------------|---|
| 1:200,000 concentration                         | 1:1,000 concentration                | <ul style="list-style-type: none"> <li>Prepared in a medicine cup with the same shape</li> <li>Could not see the label affixed to the side</li> </ul>   |
| 1:300,000 concentration                         | 1:1,000 concentration                | <ul style="list-style-type: none"> <li>Prepared in a Petri dish with the same shape</li> <li>The location and presence or absence of a lid were usually used to distinguish the two, but the lid was removed and the dish was placed next to the other</li> </ul> |
| 1:100,000 concentration                         | 1:5,000 concentration                | <ul style="list-style-type: none"> <li>Prepared in a medicine cup with the same shape</li> <li>The containers were put in separate places, but the container had been moved and placed nearer during surgery</li> </ul>   |

◆ In the reported cases, the two drugs were placed in containers with the same shape and the drug name was written on one or both of the containers.

Logo



Title

Key statement

Table and illustration to facilitate better and instant understanding of the key statement

Medical Safety Information No.191, October 2022

**Local Injection of High-Concentration Adrenaline**

**Case 1**  
In the sterilized area, the nurse prepared a Xylocaine preparation (1:200,000 concentration of adrenaline) in a medicine cup bearing the label "Xylo 1% E + NS" and Bosmin Solution 0.1% (1:1,000 concentration of adrenaline) in a medicine cup bearing the label "Bosmin (topical)." The physician first used the Xylocaine preparation for local anesthesia. Thinking that the physician would next use a gauze impregnated with Bosmin, the nurse placed the medicine cup marked "Bosmin (topical)" in front. The physician then ordered local anesthetic for a second time. The nurse drew up the drug solution from the medicine cup in front, without checking the label on the side, and passed it to the physician. After the physician injected a total of 4 mL, the patient's blood pressure rose to 230/130 mmHg and their heart rate to 130 bpm, with sporadic premature ventricular contractions and ST segment depression observed on the monitor. The nurse realized that they had handed over Bosmin Solution 0.1% in error.

**Case 2**  
The nurse prepared a Xylocaine preparation (1:300,000 concentration of adrenaline) and Bosmin Solution 0.1% (1:1,000 concentration of adrenaline) in Petri dishes of the same shape and placed them on the instrument tray. The nurse had placed the two Petri dishes away from each other and written the drug name on the lid of the Petri dish containing the Xylocaine preparation. After surgery began, the physician ordered a Bosmin injection, so the nurse passed the Petri dish containing Bosmin Solution 0.1% next to the Petri dish containing the Xylocaine preparation. The physician subsequently ordered local anesthetic, so the nurse drew up the drug solution from the Petri dish and handed it to the physician. After the physician injected 4 mL, the patient's blood pressure rose to 270 mmHg and the nurse realized that they had handed over Bosmin Solution 0.1% in error.

**Preventive/improvement measures**

- Use containers with different shapes and colors in an easily visible location when preparing preparations in the sterilized area.
- Consider changing the shape and color of containers, and prescribe internal rules.

(Comprehensive Evaluation Panel)

**Comments from experts**

◆ As part of the Project to Collect Medical Near-Miss/Adverse Event Information (a Ministry of Health, Labour and Welfare initiative), medical safety information was prepared based on the cases collected in the Project as well as the Comprehensive Evaluation Panel to prevent the occurrence and recurrence of medical adverse events. See the Project website at <http://www.med-safe.jp/>

\* Accuracy of information was ensured at the time of preparation but cannot be guaranteed in the future.  
\* This information is intended neither to limit the discretion of healthcare providers nor to impose any liability.

**Department of Adverse Event  
Japan Council for Quality Health Care**  
1-4-17 Kandamisaki-cho, Chiyoda-ku, Tokyo 101-0061 JAPAN  
Direct Tel: +81-3-5217-0252 Direct Fax: +81-3-5217-0253  
<https://www.med-safe.jp/>


Case presentations

Preventive/improvement measures

Comments from experts



# Distribution of monthly alert



**FAX**



**Notice by  
Central,  
Local  
authorities**



**Website**



**Medical institutions  
& professionals  
including 5,933\*  
institutions receiving  
it through FAX, i.e.  
approximately 70% of  
Japanese hospitals**



\* Registration figure as of March, 2023

# Database of AE / Near-miss on homepage

※現在、2010年1月～2022年9月に報告された事例を公表しています。

|   |                     |       |
|---|---------------------|-------|
| 報告事例区分  | 報告年                 |       |
| <input checked="" type="checkbox"/> 医療事故情報 <input type="checkbox"/> ヒヤリ・ハット事例   | 年～年                 |       |
| 事例の概要   |                     |       |
| <input type="checkbox"/> 薬剤 <input type="checkbox"/> 輸血 <input type="checkbox"/> 治療・処置 <input type="checkbox"/> 医療機器等 <input type="checkbox"/> ドレーン・チューブ <input type="checkbox"/> 検査 <input type="checkbox"/> 療養上の世話 <input type="checkbox"/> その他 |                     |       |
| 発生場所  | 関連診療科 (医療事故情報のみ選択可) | 当事者職種 |
|   |                     |       |
| 全文検索  |                     |       |
| キーワード入力   |                     |       |
| <input type="text"/>  |                     |       |
| <input type="button" value="検索"/>   |                     |       |

- Choose “Adverse event” and/or “Near-miss”
- Choose “Type of events”

Type key word for search : “Dialysis”

1,666 AEs are matched.

<公表している事例について>

- ・事例は医療機関からの報告時点の内容であり、報告された事例内に含まれていた個人や医療機関が特定される情報などは削除して公表しています。
- ・公表後、情報の追加・削除や事例の取り下げは行いません。
- ・医療事故情報は報告された全ての事例、ヒヤリ・ハット事例は報告する範囲に該当する一部の事例を公表しています。

表示件数   1666件

各年の事例の一覧をダウンロードはこちら

|                                |   |                                   |
|--------------------------------|---|-----------------------------------|
| <input type="checkbox"/> 事例の内容 | 患者は病棟の病室で、人工呼吸器で呼吸管理がなされ、心電図モニタを装着していた。患者の体温は38.5℃、呼吸数は20回/分、脈数は100回/分、血圧は110/70mmHg、酸素飽和度は98%であった。患者は意識が不明で、瞳孔は等大で反応あり、呼吸は浅く、SpO2は98%であった。患者は呼吸器管理がなされ、人工呼吸器で呼吸管理がなされ、心電図モニタを装着していた。患者の体温は38.5℃、呼吸数は20回/分、脈数は100回/分、血圧は110/70mmHg、酸素飽和度は98%であった。患者は意識が不明で、瞳孔は等大で反応あり、呼吸は浅く、SpO2は98%であった。 | <input type="button" value="表示"/> |
| <input type="checkbox"/> 事例の内容 | 内服薬を自己管理している患者。翌日からの1日分処方が出た為、病室にて患者に「飲んで下さい」と内服薬を渡した...  | <input type="button" value="表示"/> |
| <input type="checkbox"/> 事例の内容 | 17時40分に透析を終えた患者を日勤看護師と看護助手が透析室へ迎えに行く。看護師は透析室看護師から透析中の申し...  | <input type="button" value="表示"/> |
| <input type="checkbox"/> 事例の内容 | 多発性脳梗塞にて入院、救命のため外減圧術を施行。術後敗血症をきたし多臓器障害となった。急性腎不全に陥り、血液透...  | <input type="button" value="表示"/> |
| <input type="checkbox"/> 事例の内容 | 総胆管結石症の術後17日目、Cチューブを挿入されていたが、関連していたため、Cチューブを抜去処置を実施し...   | <input type="button" value="表示"/> |

“Browse”

“Download” in three different formats i.e. XML, PDF, CSV

# Release of alert by manufactures on sound-alike drugs: “SENIRAN vs “CERCINE” (2019)

医療関係者各位

「セニラン<sup>®</sup>錠 2mg/5mg」と「2mg/5mgセルシン<sup>®</sup>錠」の販売名類似による取り違え注意のお願い

2019年 9月

製造販売元:サンド株式会社  
製造販売元:武田テバ薬品株式会社

謹啓

時下ますますご清祥の段、お慶び申し上げます。  
また平素は格別のご高配を賜り、厚く御礼申し上げます。

さて、サンド株式会社が製造販売する「セニラン<sup>®</sup>錠 2mg/5mg (プロマゼパム) :ベンゾジアゼピン系抗不安薬」と武田テバ薬品株式会社製造販売する「2mg/5mgセルシン<sup>®</sup>錠 (ジアゼパム) :ベンゾジアゼピン系抗不安薬」とで、販売名が類似していることから、2mg/5mgセルシン<sup>®</sup>錠で調剤すべきところをセニラン<sup>®</sup>錠 2mg/5mgで調剤してしまつた事例が4件報告されております。またその逆の取り違えの事例も1件報告されております。その原因については、5件とも内服薬調剤時に確認を怠つたことによる薬剤の選択ミスであることが判明しています。

出典：公益財団法人 日本医療機能評価機構（医療事故収集等事業）「薬局ヒヤリ・ハット報告事例検索」システムより（2019年6月末時点）

このような状況から、調剤時の薬剤の選択ミスを未然に防ぐため、これらの薬剤を調剤いただく際には、販売名等を今一度ご確認くださいと共に、改めて医療機関にて周知ならびに一層のご配慮をお願い申し上げます。

なお「セニラン<sup>®</sup>錠 2mg/5mg」の製造販売元であるサンド株式会社は、根本的な再発防止対策として一般名（プロマゼパム錠 2mg/5mg「サンド」）へ名称変更手続きを進めています。名称変更の代替新規申請は本年2月に規制当局へ提出済みですが、名称変更の届出通知書にはまだ有効期間を要するところとなります。また、従来の有効期限満了期間を含めましてご不便をおかけし大変申し訳ございませんが、名称変更品を十分に流通できるまでの間は、調剤時の取り違えに十分注意いただきますよう、重ねてお願い申し上げます。



今後とも引き続きご指導ご鞭撻のほど、どうかよろしくお願い申し上げます。

謹白

- Events of drug mix-up due to phonetic similarity have been reported in JQ's national RLS.

- We have submitted a request that “**SENIRAN**”, a trade name, is removed from the market to be replaced with generic name “Bromazepam” for radical measure for prevention.

“SENIRAN” “CERCINE”  
Anti-anxiety agent Minor tranquilizer

| 製造販売元  | サンド株式会社   | 武田テバ薬品株式会社  |
|--------|---|---|
| 販売名    | セニラン <sup>®</sup> 錠 2mg<br>セニラン <sup>®</sup> 錠 5mg                                  | 2 mg セルシン <sup>®</sup> 錠<br>5 mg セルシン <sup>®</sup> 錠                                |
| 一般名    | プロマゼパム  | ジアゼパム   |
| 薬効分類名  | 精神神経安定剤   | マイナートランクワイザー  |
| PTPシート |  |  |
| お問合せ先  | サンド株式会社<br>カスタマーケアグループ<br>☎ 0120-982-001<br>受付時間 9:00~17:00<br>(土・日・祝日及び当社休日を除く)    | 武田テバDIセンター<br>☎ 0120-923-093<br>【受付時間】 9:00~17:30<br>(土日祝日・弊社休業日を除く)                |

(注) セニラン<sup>®</sup>錠は、2mg、5mgの他に1mg、3mgの規格があります。  
※製品をご使用の際は最新の添付文書をご確認ください。





PREVENTION



## Sound-alike drugs


“*Almarl*” vs “*Amaryl*”



“*Almarl*”

The brand name was **relinquished from the market** and replaced with generic name in **2012** for patient safety reason.

# Ensuring transparency through disclosure and publicity



- **Quarterly** report No. 1-72
- **Annual** report 2005-2021
- Reports are Released at press conference



**NHK News (TV News), August 29, 2016**



**MediFax (Daily Healthcare News), July 3, 2020**

# Reporting and learning system of community pharmacy (2008~)



**Community pharmacy**  
Voluntary-based

Near-miss

“Cases which **tokes** place or is identified in pharmacy”

Categories

- ✓ Prescription
- ✓ Dispensing
- ✓ Designated insured materials
- ✓ OTC: Over The Counter Drug



**Web-based reporting**

**i) Coding**

|     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 薬名  | 剤形  | 剤量  | 剤数  | 剤価  | 剤名  | 剤形  | 剤量  | 剤数  | 剤価  |
| ... | ... | ... | ... | ... | ... | ... | ... | ... | ... |

**ii) Text**

|                     |
|---------------------|
| Summary             |
| Underlying factors  |
| Preventive measures |



Japan Council for Quality Health Care  
Division of AE Prevention



Data server

**Aim : Prevention**  
**Principles : No-blame, Anonymous**

**Steering committee**  
(Experts, **Patient representative**)

**Technical panel**  
(Drug, Device, Human error)

**Secretariat**

**Annual/Half-yearly report**



**Sentinel case report**

|     |
|-----|
| ... |
| ... |
| ... |

**Iconic table**

|     |     |
|-----|-----|
| ... | ... |
| ... | ... |
| ... | ... |

**Iconic case**

|     |
|-----|
| ... |
| ... |
| ... |

**Database**


|     |     |     |
|-----|-----|-----|
| ... | ... | ... |
| ... | ... | ... |
| ... | ... | ... |



- ✓ Nation
- ✓ Community Pharmacy
- ✓ Relevant Scientific Society/Organization
- ✓ Government etc.



# 2020 WHO Patient Safety Incident Reporting and Learning Systems



## 3.3 WHO consultation on patient safety incident reporting and learning systems

In an **expert consultation** in March **2016** in **Colombo, Sri Lanka**, WHO brought together staff from ministries of health and health experts **from low- and middle-income countries** to discuss their experience of establishing and operating patient safety incident reporting and learning systems (19). The three-day meeting was attended by representatives of **18 countries** – Afghanistan, Bangladesh, Canada, Ethiopia, Ghana, India, Italy, **Japan**, Malaysia, Morocco, Nigeria, Oman, the Philippines, Poland, South Africa, Sri Lanka, Thailand and Viet Nam – and two WHO regional offices (for the South-East Asia and Eastern Mediterranean regions).



# WHO Global Patient Safety Action Plan 2021-2030



1.4  
Safety standards, regulation and accreditation

1.5  
World Patient Safety Day and Global Patient Safety Challenges

3.4  
Safety of medical devices, medicines, blood and vaccines

**Framework for Action - The 7x5 Matrix**

|   |   |  |   |   |  |   |
|---|---|--|---|---|--|---|
| 1 | 1.1 Policies to eliminate avoidable harm in health care | 1.2 Patient safety policy, strategy and implementation framework | 1.3 Resource mobilization and allocation                            | 1.4 Protective legislative measures                             | 1.5 Safety standards, regulation and accreditation                     | 1.6 World Patient Safety Day and Global Patient Safety Challenges   |
| 2 | 2.1 High-visibility systems                             | 2.2 Transparency, openness and no-blame culture                  | 2.3 Good governance for the health and managerial care system       | 2.4 Leadership capacity for clinical and managerial functions   | 2.5 Human factors/ergonomics for health systems                        | 2.6 Patient safety in emergencies and settings of extreme adversity |
| 3 | 3.1 Safety of clinical processes                        | 3.2 Safety of risk prone clinical procedures                     | 3.3 Global Patient Safety Challenge: Medication Without Harm        | 3.4 Infection prevention and control & antimicrobial resistance | 3.5 Safety of medical devices, medicines, blood and vaccines           | 3.6 Patient safety in primary care and transitions of care          |
| 4 | 4.1 Patient and family engagement                       | 4.2 Co-development of policies and programmes with patients      | 4.3 Learning from patient experience for safety improvement         | 4.4 Patient advocates and patient safety champions              | 4.5 Patient safety incident disclosure to victims                      | 4.6 Information and education to patients and families              |
| 5 | 5.1 Health worker education, skills and safety          | 5.2 Patient safety in professional education and training        | 5.3 Centres of excellence for patient safety education and training | 5.4 Patient safety competencies as regulatory requirements      | 5.5 Linking patient safety with appraisal system of health workers     | 5.6 Safe working environment for health workers                     |
| 6 | 6.1 Information, research and risk management           | 6.2 Patient safety incident reporting and learning systems       | 6.3 Patient safety information systems                              | 6.4 Patient safety surveillance systems                         | 6.5 Patient safety research programmes                                 | 6.6 Digital technology for patient safety                           |
| 7 | 7.1 Synergy, partnership and solidarity                 | 7.2 Stakeholders engagement                                      | 7.3 Common understanding and shared commitment                      | 7.4 Patient safety networks and collaboration                   | 7.5 Cross geographical and multilateral initiatives for patient safety | 7.6 Alignment with technical programmes and initiatives             |


6.1  
Patient safety incident reporting and learning systems

4.4  
Patient safety incident disclosure to victims



World Health Organization

# No-fault compensation/investigation/ prevention system for cerebral palsy , 2009~)





# Statistics of eligible case by birth year

(As of Nov 30, 2021)

| Birth year   | No. case reviewed | Eligible     |              | Not-Eligible          |              |            | Petition |
|--------------|-------------------|--------------|--------------|-----------------------|--------------|------------|----------|
|              |                   | Eligible     | Not Eligible | Preliminary to review | Total        | In process |          |
| 2009         | 561               | 419          | 142          | 0                     | 142          | 0          | Expired  |
| 2010         | 523               | 382          | 141          | 0                     | 141          | 0          | Expired  |
| 2011         | 502               | 355          | 147          | 0                     | 147          | 0          | Expired  |
| 2012         | 517               | 361          | 155          | 0                     | 155          | 0          | Expired  |
| 2013         | 476               | 351          | 125          | 0                     | 125          | 0          | Expired  |
| 2014         | 469               | 326          | 143          | 0                     | 143          | 0          | Expired  |
| 2015         | 475               | 376          | 99           | 0                     | 99           | 0          | Expired  |
| 2016         | 432               | 363          | 69           | 0                     | 69           | 0          | Expired  |
| 2017-2021    | 1,072             | 873          | 137          | 59                    | 196          | 3          | Valid    |
| <b>Total</b> | <b>4,456</b>      | <b>3,374</b> | <b>1033</b>  | <b>41</b>             | <b>1,074</b> | <b>11</b>  |          |


# Publication of Prevention Report based on aggregative analysis of Investigative Report

## Investigation committee

### Report of “Individual case”




- Cause
- Appraisal
- Preventive measures




## Prevention committee

### Report of “Aggregated cases”



- Collective analysis
- Thematic analysis
- Recommendation, etc.




- A) Report; Delivered both to **family** and **childbirth facility**
- B) Synthesized report; Posted on the web
- C) Report with identifiers deleted; Available only for research use through internal ethical process


- A) Delivered to **Childbirth facility, Scientific societies, Government, etc.**
- B) Posted on the web open to the public

# Improvement of specific practices between 2009 and 2014


## Comment on FHR monitoring for improvement



## Excess administration of oxytocin




## Mechanical ventilation within 1 min after birth






# Impact on lawsuit statistics on OB-GY



\* Preliminary data Statistics of lawsuit trend by medical specialties by the Supreme Court

# The Ockenden report findings



- Examined almost **1,600 cases** spanning **20 years**
- **201 deaths** where concerns over care found
- **131 stillbirths** and **70 neonatal deaths** affected
- Also **29 cases** where babies suffered severe **brain injuries**
- And **65 incidents** of **cerebral palsy**

OCKENDEN REPORT - FINAL

FINDINGS, CONCLUSIONS  
AND ESSENTIAL ACTIONS  
FROM THE INDEPENDENT  
REVIEW OF MATERNITY  
SERVICES  
at The Shrewsbury and  
Telford Hospital NHS Trust

Our Final Report

30 March 2022

Source: Ockenden Maternity Review



BBC, May 30<sup>th</sup>, 2022





**Select Committee: NHS Litigation Reform  
of the Health and Social Care Committee,  
House of Commons, UK Parliament**



**Rt. Hon. Jeremy  
Hunt, Chair**



**Professor Shin Ushiro  
Kyushu University Hospital,  
Japan Council for Quality  
Health Care**



**Michael Mercier, Accident  
Compensation Corporation,  
NZ**



*Dr Pelle Gustafson, Swedish  
Patient Insurer, Sweden*



*George Deebo  
Executive Officer at Virginia  
Birth-Related Neurological Injury  
Compensation Program, US*





House of Commons  
Health and Social Care  
Committee

## NHS litigation reform

Thirteenth Report of Session 2021–22

*Report, together with formal minutes relating to the report*

*Ordered by the House of Commons to be printed 20 April 2022*

HC 740  
Published on 28 April 2022  
by authority of the House of Commons

133. Professor Shin Ushiro told us that the Japanese birth injury compensation scheme had a formal process for disseminating learning and an illustration of its success was that it had recorded a reduction in the number of cases coming into the system.<sup>203</sup> In 2009, its first year of operation, 419 cases were entered into the Japanese Cerebral Palsy scheme, by 2014 that figure had reduced to 326 and even when the eligibility criteria were widened the following year eligible cases only increased to 376.<sup>204</sup> Professor Ushiro added that investigative reports into Cerebral Palsy cases increasingly find that cases have resulted from unknown genetic causes and there has been a decline in cases related to error or malpractice.<sup>205</sup>

**(As of Jun 5, 2020)**

| Birth year   | No. case reviewed | Eligible     |              | Not-Eligible          |              |            | Petition |
|--------------|-------------------|--------------|--------------|-----------------------|--------------|------------|----------|
|              |                   | Eligible     | Not Eligible | Preliminary to review | Total        | In process |          |
| 2009         | 561               | 419          | 142          | 0                     | 142          | 0          | Expired  |
| 2010         | 523               | 382          | 141          | 0                     | 141          | 0          | Expired  |
| 2011         | 502               | 355          | 147          | 0                     | 147          | 0          | Expired  |
| 2012         | 517               | 361          | 155          | 0                     | 155          | 0          | Expired  |
| 2013         | 476               | 351          | 125          | 0                     | 125          | 0          | Expired  |
| 2014         | 469               | 326          | 143          | 0                     | 143          | 0          | Expired  |
| 2015-2018    | 1,000             | 846          | 101          | 46                    | 147          | 7          | Valid    |
| <b>Total</b> | <b>4,048</b>      | <b>3,041</b> | <b>954</b>   | <b>46</b>             | <b>1,000</b> | <b>7</b>   |          |

# Takeaways

- i. JQ launched the national system in 2004 and has successfully run it with production of reports, alerts DB and so on. The products of the system have been widely utilized for practical and research use.
- ii. Equivalent systems were built step-by-step such as systems for community pharmacy and perinatal care. No-fault compensation/investigation/prevention system for cerebral palsy is so unique that deserves distribution on global basis.
- iii. Japan including JQ is keen to work in close cooperation with global community on patient safety as expected by WHO which launched Global Patient Safety Action Plan 2021-2030.





**World  
Patient Safety  
Day** 17 September



**World Health  
Organization**